Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chin Lin

Showing results (1431-1440 of 1,492) with videos related to

Pageof 150
Sort By:
Annals of Hematology|November 12, 2021
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experienceYu-Wen Wang, Xavier Cheng-Hong Tsai, Hsin-An Hou, et al.
Clinical and Experimental Medicine|September 25, 2023
Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working GroupHarinder Gill, Garret M K Leung, Melissa G M Ooi, et al.
Blood Cancer Journal|August 9, 2023
Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classificationWan-Hsuan Lee, Ming-Tao Tsai, Cheng-Hong Tsai, et al.
Blood Cancer Journal|March 13, 2026
Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus ClassificationWan-Hsuan Lee, Hsin-An Hou, Chien-Chin Lin, et al.
Blood Cancer Journal|April 9, 2024
Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasmsWan-Hsuan Lee, Chien-Chin Lin, Cheng-Hong Tsai, et al.
Pediatric Blood & Cancer|February 1, 2021
RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletionsYing-Jung Huang, Hsi-Che Liu, Tang-Her Jaing, et al.
American Journal of Hematology|April 12, 2014
SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolutionChien-Chin Lin, Hsin-An Hou, Wen-Chien Chou, et al.
The Lancet. Haematology|July 22, 2024
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, et al.
Nurse Education Today|February 26, 2022
Nursing students' and faculty members' experiences of online education during COVID-19 across Southeast Asia: A Photovoice studyWipada Kunaviktikul, Emily Ang, Ns Syamikar Baridwan, et al.
Blood Research|December 26, 2025
Prognostic impact of lymphocyte to monocyte ratio in patients with myelodysplastic neoplasms/syndromesWan-Hsuan Lee, Chien-Chin Lin, Xavier Cheng-Hong Tsai, et al.
Pageof 150

Showing results (1431-1440 of 1,492) with videos related to

Sort By:
Pageof 150
Annals of Hematology|November 12, 2021
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experienceYu-Wen Wang, Xavier Cheng-Hong Tsai, Hsin-An Hou, et al.
Clinical and Experimental Medicine|September 25, 2023
Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working GroupHarinder Gill, Garret M K Leung, Melissa G M Ooi, et al.
Blood Cancer Journal|August 9, 2023
Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classificationWan-Hsuan Lee, Ming-Tao Tsai, Cheng-Hong Tsai, et al.
Blood Cancer Journal|March 13, 2026
Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus ClassificationWan-Hsuan Lee, Hsin-An Hou, Chien-Chin Lin, et al.
Blood Cancer Journal|April 9, 2024
Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasmsWan-Hsuan Lee, Chien-Chin Lin, Cheng-Hong Tsai, et al.
Pediatric Blood & Cancer|February 1, 2021
RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletionsYing-Jung Huang, Hsi-Che Liu, Tang-Her Jaing, et al.
American Journal of Hematology|April 12, 2014
SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolutionChien-Chin Lin, Hsin-An Hou, Wen-Chien Chou, et al.
The Lancet. Haematology|July 22, 2024
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, et al.
Nurse Education Today|February 26, 2022
Nursing students' and faculty members' experiences of online education during COVID-19 across Southeast Asia: A Photovoice studyWipada Kunaviktikul, Emily Ang, Ns Syamikar Baridwan, et al.
Blood Research|December 26, 2025
Prognostic impact of lymphocyte to monocyte ratio in patients with myelodysplastic neoplasms/syndromesWan-Hsuan Lee, Chien-Chin Lin, Xavier Cheng-Hong Tsai, et al.
Pageof 150